PeptideJournal
Guides18 min read

Best Peptides for Cardiovascular Health

Heart disease kills more people worldwide than any other condition — over 17 million each year. Standard medications like statins, beta-blockers, and ACE inhibitors manage symptoms well.

Heart disease kills more people worldwide than any other condition — over 17 million each year. Standard medications like statins, beta-blockers, and ACE inhibitors manage symptoms well. But they rarely address what goes wrong at the cellular level: damaged blood vessel linings, failing mitochondria, chronic low-grade inflammation, and impaired tissue repair.

That gap is where peptide research gets interesting.

Over the past two decades, scientists have identified several peptides — short chains of amino acids — that target the root mechanisms of cardiovascular damage. Some promote new blood vessel growth. Others protect heart cells during oxygen deprivation. A few regulate blood pressure through pathways that existing drugs don't touch.

None of these peptides replace your cardiologist's treatment plan. But the research behind them is real, growing, and worth understanding.

Table of Contents

How Peptides Affect the Cardiovascular System

Your cardiovascular system is more than just a pump and pipes. It's a dynamic network of cells that constantly repair themselves, grow new vessels, regulate blood pressure, and manage inflammation. Peptides participate in all of these processes.

Here's how the key mechanisms break down:

Endothelial protection. The endothelium — the thin layer of cells lining every blood vessel — is the first casualty of cardiovascular disease. When it's damaged, plaques form, arteries stiffen, and blood pressure rises. Several peptides directly protect and repair endothelial cells.

Angiogenesis. After a heart attack or in chronic ischemia, the heart needs new blood vessels to restore oxygen delivery. Certain peptides stimulate angiogenesis — the growth of new vessels from existing ones.

Anti-inflammation. Chronic inflammation drives atherosclerosis, weakens heart muscle, and promotes clot formation. Peptides that reduce inflammatory cytokines (like TNF-alpha and IL-6) without suppressing the entire immune system are particularly valuable.

Mitochondrial support. Heart cells consume enormous amounts of energy. When their mitochondria fail — due to aging, diabetes, or ischemia — the heart weakens. Mitochondrial-derived peptides and mitochondria-targeting peptides address this directly.

Anti-fibrotic effects. After injury, scar tissue (fibrosis) replaces functioning heart muscle. Peptides that limit fibrosis help preserve cardiac function over time.

BPC-157: Vascular Repair and Endothelial Protection

BPC-157 is a 15-amino-acid peptide derived from a protein found in human gastric juice. Most people know it for wound healing and gut repair, but the cardiovascular research is extensive and consistent.

What the Studies Show

A 2020 study in Scientific Reports provided the first clear mechanism for BPC-157's vascular effects. Researchers demonstrated that BPC-157 causes concentration-dependent vasodilation in isolated rat aortas — and this effect depends on a healthy endothelium. Remove the endothelium, and the vasodilation drops significantly [1].

The mechanism works through the Src-Caveolin-1-eNOS pathway. BPC-157 stimulates phosphorylation of Caveolin-1, which releases endothelial nitric oxide synthase (eNOS) from its inhibited state. The result: a 1.35-fold increase in nitric oxide production in vascular endothelial cells [1].

Nitric oxide is the body's most important vasodilator. It relaxes blood vessel walls, prevents platelet clumping, and inhibits the inflammatory processes that lead to atherosclerosis.

Angiogenesis Through VEGFR2

A separate study found that BPC-157 increases vessel density both in living animals and in cell cultures. It accelerated blood flow recovery in rats with ischemic hind limbs. The peptide works by upregulating VEGFR2 (vascular endothelial growth factor receptor 2) — not by increasing VEGF itself, but by increasing the receptor that responds to it [2].

This is a meaningful distinction. VEGF-based therapies have been tried and often disappointed in clinical trials. Working at the receptor level may offer a different, potentially more effective approach.

Broader Cardiovascular Effects

A comprehensive 2022 review in Biomedicines catalogued BPC-157's effects across cardiac pathology models: myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, and thrombosis. The review concluded that BPC-157 maintains endothelium function, prevents and reverses thrombosis formation, and preserves platelet function in animal models [3].

An earlier review called BPC-157 "the most potent angiomodulatory agent" studied, citing its ability to act through multiple vasoactive pathways — NO, VEGF, and FAK (focal adhesion kinase) — simultaneously [4].

Limitations

All of this data comes from animal models and cell cultures. No human clinical trials have tested BPC-157 specifically for cardiovascular endpoints. The peptide was in Phase II trials for inflammatory bowel disease (under designations PL-10 and PL14736), but cardiovascular-specific human data is still missing.

TB-500 (Thymosin Beta-4): Cardiac Regeneration After Injury

TB-500 is a synthetic fragment of thymosin beta-4 (Tb4), a 43-amino-acid peptide that regulates actin, a protein fundamental to cell movement and structure. The cardiac research on Tb4 is some of the most compelling in regenerative medicine.

The Landmark Finding

In 2007, researchers published a pivotal study showing that Tb4 is cardioprotective after myocardial infarction in mice. But they discovered something unexpected: Tb4 didn't just protect — it activated epicardial progenitor cells, a population of stem-like cells in the heart's outer lining that are normally dormant in adults [5].

This made Tb4 the first known molecule to initiate simultaneous myocardial and vascular regeneration after systemic (whole-body) administration [5].

How It Works

Tb4's cardiac benefits work through several overlapping pathways:

  • Cell survival: Tb4 activates Akt (protein kinase B), a key survival kinase that protects heart cells from death during oxygen deprivation [6].
  • Angiogenesis: It promotes new blood vessel growth in damaged cardiac tissue, working alongside VEGF to improve blood supply after heart attacks [7].
  • Anti-fibrotic effects: Tb4 reduces scar tissue formation after cardiac injury — a major factor in preserving long-term heart function [7].
  • Epicardial reactivation: Perhaps most remarkably, Tb4 "rewinds" the biological clock in the adult heart, reactivating embryonic developmental programs. This process occurs even without injury, suggesting Tb4 can prime the heart for better repair capacity [6].

Animal Model Results

In mouse models of myocardial infarction, Tb4 treatment reduced infarct size, limited left ventricular remodeling, and improved cardiac function. Pig models — which more closely resemble human hearts — showed similar improvements. The AGES domain (the C-terminal four amino acids of Tb4) was identified as the essential region responsible for cardiac benefits [8].

A study in the Journal of the American Heart Association also found that circulating Tb4 levels are elevated in women with heart failure with preserved ejection fraction (HFpEF), suggesting the body naturally upregulates this peptide in response to cardiac stress [9].

Current Status

Despite strong preclinical evidence, Tb4/TB-500 has not yet completed large-scale human clinical trials for cardiac indications. RegeneRx Biopharmaceuticals has studied Tb4 in clinical trials for wound healing, with cardiac applications representing a potential future direction.

GHK-Cu: The Copper Peptide With Vascular Benefits

GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It circulates in human blood plasma at about 200 ng/ml at age 20, dropping to 80 ng/ml by age 60 [10]. Most research focuses on its skin and wound-healing properties, but its vascular effects deserve attention.

Fibrinogen and Cardiovascular Risk

GHK was originally isolated from blood plasma as a molecule that suppresses fibrinogen synthesis [10]. This matters for cardiovascular health because elevated fibrinogen is a top-tier risk factor for heart disease.

The Prospective Cardiovascular Munster (PROCAM) study followed 5,389 men for 10 years and found that men in the top third of plasma fibrinogen levels had a 2.4-fold higher rate of coronary events compared to those in the bottom third [10]. Similar findings came from Scottish cardiovascular cohorts.

Fibrinogen doesn't just form clots. It increases blood viscosity by causing red blood cells to stack (rouleaux formation), reducing flow through small vessels. A peptide that naturally suppresses fibrinogen — and declines with age — is directly relevant to cardiovascular disease progression.

Blood Vessel Restoration

GHK-Cu supports vascular health through three related mechanisms:

  1. Angiogenesis: It increases expression of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), both of which drive new blood vessel formation [10].
  2. Collagen and elastin synthesis: These structural proteins maintain blood vessel wall integrity. GHK-Cu stimulates their production, which is relevant for maintaining arterial elasticity with age [10].
  3. SPARC-mediated repair: When blood vessels are damaged, endothelial cells produce a protein called SPARC (secreted protein, acidic and rich in cysteine) that contains the GHK sequence. Tissue proteases break down SPARC, releasing GHK peptides that stimulate repair [10].

Antioxidant and Anti-Inflammatory Effects

Gene expression studies show that GHK increases the expression of 14 antioxidant genes while suppressing 2 pro-oxidant genes. It also stimulates 47 DNA repair genes [11]. In macrophage cell cultures, GHK-Cu pretreatment significantly decreased reactive oxygen species (ROS) levels, increased superoxide dismutase (SOD) activity, and reduced TNF-alpha and IL-6 production through suppression of NF-kB and p38 MAPK signaling [11].

Free radical damage and chronic inflammation are central to atherosclerosis. A peptide that addresses both — while also suppressing fibrinogen — hits multiple cardiovascular risk factors simultaneously.

Practical Limitations

GHK-Cu has a very short half-life in plasma (under 30 minutes) and is rapidly cleared after injection. Its effects on gene expression and signaling seen in cell culture may not translate directly to systemic cardiovascular outcomes. No clinical trials have specifically studied GHK-Cu for heart disease or atherosclerosis prevention.

Angiotensin-(1-7): The Protective Arm of the RAS

Angiotensin 1-7 is the "good" member of the renin-angiotensin system (RAS). While angiotensin II — the target of ACE inhibitors and ARBs — drives vasoconstriction, inflammation, and cardiac remodeling, angiotensin-(1-7) does the opposite.

How It Works

Angiotensin-(1-7) is produced by ACE2 (the same enzyme that doubles as the SARS-CoV-2 entry receptor). It acts through the Mas receptor to produce vasodilation, reduce inflammation, and inhibit fibrosis and cardiac hypertrophy [12].

Think of the RAS as a balance scale. Angiotensin II tips the scale toward damage. Angiotensin-(1-7) tips it toward protection. Most cardiovascular drugs work by blocking the damaging side. Angiotensin-(1-7) research asks: what if we strengthened the protective side instead?

Human Data

A study published in Circulation: Heart Failure measured the angiotensin 1-7/angiotensin II ratio in heart failure patients and found that an elevated ratio independently predicted better outcomes — fewer deaths and shorter hospital stays — even after adjusting for age, BNP levels, NYHA class, and other standard risk factors [13].

This is significant because it suggests the protective arm of the RAS has real clinical relevance in humans, not just animal models.

Animal Studies

In transgenic mice engineered to produce 8-fold more angiotensin-(1-7) in their hearts, researchers found significantly less ventricular hypertrophy and fibrosis in response to hypertension — with no change in resting blood pressure or baseline cardiac function. This was the first evidence of a direct cardiac protective effect of angiotensin-(1-7) independent of blood pressure reduction [14].

Additional studies showed protection against diastolic dysfunction from mineralocorticoid excess and improved recovery from ischemia-reperfusion injury in diabetic hypertensive rats [15].

Clinical Translation

Recombinant human ACE2 (which increases angiotensin-(1-7) while decreasing angiotensin II) has entered Phase II clinical trials. A systematic review found 39 studies examining angiotensin-(1-7) in cardiovascular contexts, though only one small interventional study in human heart failure patients (n=8) has been completed [16]. More human trials are clearly needed.

MOTS-c and Humanin: Mitochondrial Peptides for Heart Protection

MOTS-c and Humanin are mitochondrial-derived peptides (MDPs) — small proteins encoded not in nuclear DNA, but in mitochondrial DNA. Their discovery has opened a new chapter in cardiovascular biology.

Why Mitochondria Matter for the Heart

Your heart beats about 100,000 times per day and never rests. Heart cells (cardiomyocytes) contain more mitochondria than any other cell type — roughly 5,000 per cell, occupying about 35% of the cell volume. When mitochondria fail, the heart follows.

Mitochondrial dysfunction drives atherosclerosis, heart failure, ischemia-reperfusion injury, and diabetic cardiomyopathy. MDPs appear to be the mitochondria's built-in repair signals [17].

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. It functions as an exercise mimetic — activating the same AMPK pathway that exercise does — and regulates glucose utilization, fat oxidation, and inflammatory signaling [18].

Cardiovascular relevance:

  • Blood MOTS-c levels are lower in people with type 2 diabetes, coronary endothelial dysfunction, and obesity [18].
  • MOTS-c levels decline with age: young adults have 11-21% higher levels than middle-aged and older adults [18].
  • A 2025 study in Frontiers in Physiology showed that MOTS-c restores mitochondrial respiration in diabetic heart tissue, suggesting a direct therapeutic application for diabetic cardiomyopathy [19].

Humanin

Humanin is a 24-amino-acid peptide, also encoded in mitochondrial DNA, with anti-apoptotic and anti-inflammatory properties. In cardiovascular research, it has shown protective effects against atherosclerosis, myocardial ischemia-reperfusion injury, and endothelial dysfunction [17].

Both MDPs share similar signaling pathways and may work together. A 2025 review in Experimental and Therapeutic Medicine concluded that MDPs "modulate apoptosis, inflammation and oxidative stress in the cardiovascular system" and protect against atherosclerosis, stroke, heart failure, and microvascular diseases [20].

The Big Picture

MDPs represent an entirely different approach to cardiac protection — one that works from the energy-production machinery outward, rather than from the outside in. This field is young but growing rapidly.

Natriuretic Peptides: From Biomarker to Treatment

Natriuretic peptides are the most clinically established peptides in cardiology. If you've been to an emergency room with shortness of breath, you've probably had your BNP (B-type natriuretic peptide) or NT-proBNP levels checked.

The Diagnostic Role

BNP is released by heart ventricles in response to stretching from volume or pressure overload. It's the gold-standard biomarker for heart failure diagnosis and prognosis.

A 2023 scientific statement from the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America, and the Japanese Heart Failure Society reaffirmed BNP and NT-proBNP as essential tools for diagnosing heart failure and guiding treatment decisions [21].

Natriuretic Peptides as Treatment: Nesiritide

The natriuretic peptide family (ANP, BNP, CNP) naturally promotes vasodilation, sodium excretion, and diuresis while inhibiting cardiac remodeling. This made them attractive drug candidates.

Nesiritide — recombinant human BNP — was FDA-approved in 2001 for acute decompensated heart failure. It produces rapid vasodilation, reduces pulmonary wedge pressure, improves cardiac output, and provides symptomatic relief [22].

However, the large ASCEND-HF trial (7,141 patients) showed that while nesiritide was safe for kidneys (contradicting earlier concerns), it didn't significantly reduce re-hospitalization or death compared to standard therapy [22]. Its clinical use has since declined.

Neprilysin Inhibition: The Modern Approach

The more successful strategy has been to prevent the breakdown of the body's own natriuretic peptides. Sacubitril/valsartan (Entresto) combines a neprilysin inhibitor with an ARB, boosting endogenous natriuretic peptide levels. The PARADIGM-HF trial showed this approach reduces cardiovascular death and heart failure hospitalization by 20% compared to enalapril alone [23].

This is the clearest example of peptide biology translating into a major clinical breakthrough.

SS-31 (Elamipretide): Targeting Mitochondrial Membranes

SS-31 is a synthetic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that concentrates in mitochondrial inner membranes, where it stabilizes cardiolipin — a phospholipid essential for electron transport chain function.

Mechanism

Unlike MOTS-c and humanin, which are signaling peptides, SS-31 works as a structural stabilizer. It binds to cardiolipin, preventing the mitochondrial membrane damage that occurs during ischemia, aging, and heart failure. This improves ATP production and reduces reactive oxygen species generation at the source [24].

Clinical Trials

SS-31 (marketed as elamipretide by Stealth BioTherapeutics) has been the subject of multiple clinical trials:

  • The EMBRACE-STEMI trial tested elamipretide in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
  • The PROGRESS-HF trial evaluated elamipretide in patients with heart failure with reduced ejection fraction.
  • The TAZPOWER trial examined elamipretide for Barth syndrome, a genetic mitochondrial cardiomyopathy.

Results have been mixed. While the Barth syndrome data was promising enough to pursue FDA consideration, the broader heart failure trials have not yet demonstrated definitive clinical benefit [24]. The concept remains scientifically sound, and further trials are ongoing.

Peptide Comparison Table

PeptidePrimary Cardiovascular MechanismResearch StageKey Evidence
BPC-157Endothelial protection, angiogenesis via VEGFR2, NO modulationPreclinical (animal/in vitro)Consistent vascular effects across dozens of animal studies
TB-500Cardiac regeneration, epicardial progenitor activation, anti-fibroticPreclinical (mouse/pig)First molecule to initiate simultaneous myocardial and vascular regeneration
GHK-CuFibrinogen suppression, antioxidant gene activation, vascular repairPreclinical (in vitro/gene expression)Addresses multiple CVD risk factors; very short half-life
Angiotensin-(1-7)Counter-regulates RAS — vasodilation, anti-fibrosis, anti-hypertrophyPreclinical + early clinicalHuman prognostic data; ACE2 in Phase II trials
MOTS-cAMPK activation, mitochondrial respiration, metabolic regulationPreclinicalLower levels linked to diabetes, coronary dysfunction, aging
HumaninAnti-apoptotic, anti-inflammatory, mitochondrial protectionPreclinicalProtective against atherosclerosis and I/R injury in models
Natriuretic PeptidesVasodilation, diuresis, anti-remodelingFDA-approved (diagnostic); clinical use (therapeutic)BNP/NT-proBNP standard for HF diagnosis; neprilysin inhibitors reduce mortality
SS-31Cardiolipin stabilization, mitochondrial membrane protectionClinical trials (Phase II/III)Mixed results; promising for mitochondrial cardiomyopathies

What the Research Doesn't Tell Us Yet

Honesty matters more than hype. Here's what remains unclear:

Human trial data is thin for most peptides. BPC-157, TB-500, GHK-Cu, MOTS-c, and humanin have not completed large-scale human cardiovascular trials. Natriuretic peptides and SS-31 are the exceptions — and even their therapeutic applications have produced mixed results.

Dosing for cardiovascular endpoints is unknown. Most preclinical studies use doses and routes (intraperitoneal injection in rats, transgenic overexpression in mice) that don't translate directly to human clinical use.

Long-term safety is unstudied. Peptides that promote angiogenesis and cell growth (BPC-157, TB-500) raise theoretical questions about cancer risk with chronic use. No long-term human safety data exists for most of these compounds.

Regulatory status is uncertain. Most research peptides are not FDA-approved for cardiovascular use. BPC-157 is on WADA's prohibited list. Natriuretic peptide biology has been successfully leveraged through neprilysin inhibitors, but direct peptide administration (nesiritide) has fallen out of favor.

Synergistic effects are largely unexplored. Many of these peptides target complementary pathways. Whether combining them (as some peptide stacking protocols suggest) produces additive or dangerous effects remains unknown.

Frequently Asked Questions

Are any peptides FDA-approved for heart disease?

Not as direct therapeutics in the way most people think of it. BNP and NT-proBNP are FDA-approved as diagnostic biomarkers for heart failure. Nesiritide (recombinant BNP) was FDA-approved for acute decompensated heart failure in 2001, though its use has declined. The biggest clinical success has been sacubitril/valsartan, which boosts endogenous natriuretic peptide levels by inhibiting the enzyme that breaks them down.

Can peptides replace heart medications?

No. Peptides are not designed to replace statins, beta-blockers, ACE inhibitors, or other established cardiovascular drugs. The research suggests potential complementary roles, but no peptide has been proven in human trials to match the benefits of standard heart failure or hypertension medications.

Which peptide has the strongest cardiovascular evidence?

Natriuretic peptides have the most human clinical data, and their biology has been successfully translated into sacubitril/valsartan (Entresto). For regenerative applications, thymosin beta-4 (TB-500) has the most compelling preclinical evidence for actual cardiac tissue repair. Angiotensin-(1-7) has the strongest human prognostic data among the research peptides.

Are cardiovascular peptides safe?

Safety profiles in animal studies have generally been favorable, with no major toxic effects reported for BPC-157, TB-500, or GHK-Cu at studied doses. However, "safe in rats" doesn't mean "safe in humans at any dose, long-term." Anyone considering peptide therapy should work with a qualified physician who understands both the potential benefits and the limitations of the current evidence.

How do mitochondrial peptides differ from other cardiovascular peptides?

Mitochondrial-derived peptides (MOTS-c, humanin) work from the inside out — they're produced by the cell's energy machinery and regulate metabolic and stress responses. Most other cardiovascular peptides work from the outside in — binding to cell surface receptors to trigger repair or protection. SS-31 is a synthetic peptide that targets mitochondrial membranes directly. This inside-out approach may be especially relevant for diabetic cardiomyopathy and age-related heart failure, where mitochondrial dysfunction is a primary driver.

The Bottom Line

Cardiovascular peptide research is real science, not marketing hype — but it's also mostly early science. The strongest clinical evidence supports natriuretic peptide biology (now harnessed through neprilysin inhibitors like sacubitril/valsartan). For everything else, the animal data is promising and mechanistically sound, but human trials are either small, incomplete, or not yet started.

The most interesting aspect of this field isn't any single peptide — it's the collective picture. BPC-157 addresses endothelial dysfunction. TB-500 activates dormant repair cells. GHK-Cu suppresses fibrinogen and oxidative stress. Angiotensin-(1-7) rebalances the renin-angiotensin system. Mitochondrial peptides protect the heart's energy supply. Each targets a different failure point in cardiovascular disease.

Whether these peptides eventually become standard treatments — alone, in combination, or as inspiration for new drug designs — depends on the clinical trials still ahead. For now, the research provides a useful map of where cardiovascular medicine might go next.

For related reading, see our guides on best peptides for anti-aging and longevity, best peptides for inflammation reduction, and best peptides for men over 40.

References

  1. Hsieh MJ, Liu HT, Wang CN, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports. 2020;10(1):17078. PubMed

  2. Hsieh MJ, Lee CH, Chueh HY, et al. Therapeutic potential of pro-angiogenic BPC 157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333. PubMed

  3. Seiwerth S, Brcic L, Vuletic LB, et al. Stable gastric pentadecapeptide BPC 157 as useful cytoprotective peptide therapy in the heart disturbances, myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, and thrombosis presentation. Biomedicines. 2022;10(11):2696. PubMed

  4. Sikiric P, Seiwerth S, Rucman R, et al. BPC 157 and blood vessels. Current Pharmaceutical Design. 2014;20(7):1014-1024. PubMed

  5. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 is cardioprotective after myocardial infarction. Circulation Research. 2007;100(3):e50-e57. PubMed

  6. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 and cardiac repair. Journal of Molecular and Cellular Cardiology. 2010;48(6):1064-1068. PubMed

  7. Shrivastava S, Srivastava D, Olson EN, et al. Thymosin beta4: A multi-faceted tissue repair stimulating protein in heart injury. International Journal of Molecular Sciences. 2019;20(6):1491. PubMed

  8. Goldstein AL, Hannappel E, Sosne G, et al. C-terminal variable AGES domain of Thymosin beta4: the molecule's primary contribution in support of post-ischemic cardiac function and repair. Journal of Molecular and Cellular Cardiology. 2015;87:36-45. PubMed

  9. Shah SJ, Lam CSP, Svedlund S, et al. Thymosin beta-4 is elevated in women with heart failure with preserved ejection fraction. Journal of the American Heart Association. 2017;6(12):e005586. JAHA

  10. Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: Resetting the human genome to health. BioMed Research International. 2014;2014:151479. Wiley Online Library

  11. Pickart L, Vasquez-Soltero JM, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987. PMC

  12. Santos RA, Ferreira AJ, Verano-Braga T, et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nature Reviews Drug Discovery. 2014;13(4):278-289. PubMed

  13. Wang J, Li N, Gao F, et al. Elevated angiotensin 1-7/angiotensin II ratio predicts favorable outcomes in patients with heart failure. Circulation: Heart Failure. 2020;13(7):e006939. AHA Journals

  14. Santos RA, Castro CH, Gava E, et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circulation Research. 2008;103(12):1319-1326. PubMed

  15. Singh K, Singh T, Sharma PL. Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats. Pharmacology. 2009;84(3):143-148. PubMed

  16. Defined Health, et al. A systematic review to investigate whether Angiotensin-(1-7) is a promising therapeutic target in human heart failure. Heart Failure Reviews. 2014;19(3):367-377. PubMed

  17. Zhu Y, Xian X, Wang Z, et al. Mitochondrial-derived peptides in cardiovascular disease: Novel insights and therapeutic opportunities. Journal of Advanced Research. 2023;37:100530. ScienceDirect

  18. Lee C, Zeng J, Drew BG, et al. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023;14:1120533. PMC

  19. Li X, et al. Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart. Frontiers in Physiology. 2025;16:1602271. Frontiers

  20. Chen Y, et al. Mitochondria-derived peptides: Promising microproteins in cardiovascular diseases (Review). Experimental and Therapeutic Medicine. 2025;29(5):86. PMC

  21. Mueller C, McDonald K, de Boer RA, et al. Natriuretic peptides: Role in the diagnosis and management of heart failure. Journal of Cardiac Failure. 2023;29(4):S42-S70. Journal of Cardiac Failure

  22. Patel N, Cushman M. Nesiritide — A new agent for acute decompensated heart failure. International Journal of Clinical Practice. 2016;70(4):S86. PMC

  23. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). New England Journal of Medicine. 2014;371(11):993-1004.

  24. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology. 2014;171(8):2029-2050.